• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 10 of 100
Just 25% of people at high risk of pneumococcal disease—children younger than 2, adults older than 64, and those with certain chronic health conditions such as diabetes—have been immunized, according to an August 2024 survey by the National Foundation for Infectious Diseases.
HealthPneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination
By Lindsey LeakeOctober 22, 2024
LeadershipHow Merck leveled up its cybersecurity strategy since the NotPetya cyberattack that led to a $1.4 billion dispute
By John KellOctober 22, 2024
France's Prime Minister Michel Barnier speaking to reporters.
HealthFrench government ‘must block the sale’ of Sanofi’s Doliprane painkiller to U.S. private equity, critics argue
By Jurgen Hecker, Tom Barfield and AFPOctober 22, 2024
Anne Wojcicki, chief executive officer and co-founder of 23andMe
Leadership23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable
By Lila MacLellanOctober 17, 2024
CommentaryThe world needs innovative antiviral drugs—but market incentives won’t align until it’s too late, Germany’s ‘head of challenges’ warns
By Jano CostardOctober 16, 2024
HealthWalgreens to close 1,200 stores over next three years
By Chris MorrisOctober 15, 2024
RetailFrance’s top-selling painkiller may be sold to the U.S. and is causing the nation a splitting headache
By Jurgen Hecker and AFPOctober 15, 2024
CommentaryHere are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
By Jeffrey Sonnenfeld and Steven TianOctober 10, 2024
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
HealthMost Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
RetailBritish pharma giant GSK strikes $2.3 billion deal to put an end to 80,000 U.S. lawsuits
By AFPOctober 10, 2024
CommentarySome businesses are now backtracking on DEI. Biopharma cannot afford to and must remain resolute
By Robert BlumOctober 9, 2024
Martin Shkreli holds his head, as if he knows how much of a headache it's going to be to convince the Supreme Court to overturn his case
PoliticsMartin Shkreli gets snubbed by the Supreme Court and must return millions he reaped from jacking up the price of a lifesaving drug
By Lindsay Whitehurst and The Associated PressOctober 7, 2024
Google DeepMind director of strategic initiatives, Terra Terwilliger, speaking onstage at Fortune's COO Summit.
TechGoogle DeepMind exec says AI will increase efficiency so much it’s expected to handle 50% of info requests in its legal department
By Paolo ConfinoOctober 7, 2024
Albert Bourla puts his palm flat on tup of his other hand, rolled up in a fist, as he sits and listens to a question onstage at a conference.
FinancePfizer stock surges 3% after activist Starboard takes $1 billion stake, taps former execs
By Greg McKennaOctober 7, 2024
balding head
HealthHair loss drug probed in Europe over link to suicidal thoughts
By Ashleigh Furlong and BloombergOctober 4, 2024
1...
  • 8
  • 9
  • 10
  • 11
  • 12
...100
Most Popular
Success
In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’An image of a popular article
By Emma BurleighFebruary 2, 2026
Cybersecurity
Top AI leaders are begging people not to use Moltbook, a social media platform for AI agents: It’s a ‘disaster waiting to happen’An image of a popular article
By Eva RoytburgFebruary 2, 2026
Politics
Meet the Palm Beach billionaire who paid $2 million for a private White House visit with TrumpAn image of a popular article
By Tristan BoveFebruary 3, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.